Ads
related to: depo provera 10 weeks pregnant- How Does It Work?
Learn How This Birth Control
Option Works Differently.
- Cost & Insurance Coverage
Learn About Cost
& Insurance Coverage.
- Healthcare Provider Site
Visit The Official HCP
Website For More Information.
- Contact Us
Contact Us For More Information
About This Birth Control Option.
- How Does It Work?
Search results
Results From The WOW.Com Content Network
DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. [ 38 ] [ 39 ] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot , from which it is slowly released over a period ...
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [ 5 ] – 200 mg (intramuscularly) every 2 months [ 3 ]
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
CICs are different from progestogen-only injectable contraceptives (POICs), such as depot medroxyprogesterone acetate (DMPA; brand names Depo-Provera, Depo-SubQ Provera 104) and norethisterone enantate (NETE; brand name Noristerat), which are not combined with an estrogen and are given once every two to three months instead of once a month. [2]
Depo-medroxyprogesterone acetate (Depo-Provera, "Depo"). Depo-medroxyprogesterone may have benefits for catamenial epilepsy . Check seizure frequency and consider a shorter dosage interval (e.g., 10 weeks) if seizure frequency increases prior to the next dose (especially if on an enzyme-inducing ASM).
Contraceptive Technology reports a typical failure rate of 3% per year for the injection Depo-Provera, and 8% per year for most other user-dependent hormonal methods. [10] While no large studies have been done, it is hoped that newer methods which require less frequent action (such as the patch) will result in higher user compliance and ...